Karuna’s Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade) (NASDAQ:KRTX)

wildpixel Introduction Karuna Therapeutics (NASDAQ:KRTX) develops innovative treatments for psychiatric and neurological disorders. Their investigational drug, KarXT, targets schizophrenia and Alzheimer’s-related psychosis with a unique mechanism, differing from dopaminergic or serotonergic pathways, offering a potential new treatment option. In my previous analysis of Karuna Therapeutics, I highlighted the potential of their antipsychotic drug, KarXT, to…

Read More